CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)

-0.01  -3%
Previous Close 0.51
Open 0.51
Price To Book 4.5
Market Cap 11106682
Shares 22,437,741
Volume 213,009
Short Ratio 2.96
Av. Daily Volume 342,104

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 failed to meet endpoint - July 2016
Piclidenoson (CF101)
Phase 2 data did not meet primary endpoint - March 27, 2019. Presentation at ASCO June 02, 2019 8:00 am CDT.
Namodenoson (CF102)
Cancer - advanced liver cancer second line
Phase 3 continues to enrol as of March 28. 2019.
Piclidenoson (CF101)
Rheumatoid arthritis
Phase 2/3 trial did not meet primary endpoint late March 2015. Additional Phase 3 trial initiation announced August 21, 2018.
Piclidenoson (CF101)
Phase 2 data due 2H 2019.
Namodenoson (CF102)
Non-alcoholic steatohepatitis (NASH)

Latest News

  1. Can-Fite Receives $1,000,000 Payment from CKD for Distribution of Namodenoson in South Korea
  2. Can-Fite Announces Late-Breaking Abstract Presentation on Namodenoson™ Phase II Results at the American Association of Clinical Oncology (ASCO) Annual Meeting
  3. Can-Fite BioPharma Announces $3.2 Million Registered Direct Offering
  4. Can-Fite Files Annual Report for the Year Ended December 31, 2018
  5. Can-Fite Reports 2018 Financial Results & Provides Clinical Update
  6. Can-Fite Announces Phase II Advanced Liver Cancer Top-Line Results for its Orphan/Fast Track Drug Namodenoson
  7. Four Marijuana Stocks on the Rise on Wednesday
  8. Can-Fite to Participate in Bio Asia International Conference on March 5-6, 2019 in Tokyo
  9. Can-Fite Expands its Namodenoson Distribution Deal with CKD in South Korea with NASH Indication
  10. Watch These 4 Healthcare Stocks Set The Pace On Monday (2/4/19)
  11. Can-Fite Receives Notice of Allowance From U.S. Patent and Trademark Office for Osteoarthritis Drug
  12. 4 Healthcare Stocks Raising The Bar On Wednesday (1/30/19)
  13. Can-Fite’s Drugs’ Potential Ability to Treat Cytokine Release Syndrome in Cancer Immunotherapy Published in Scientific Journal
  14. Can-Fite BioPharma CEO Letter to Shareholders
  15. Can-Fite BioPharma Announces Registered Direct Offering
  16. Can-Fite: Pre-Clinical Data Positions Namodenoson as an anti-Obesity Agent
  17. Can-Fite to Participate in the Biotech Showcase™ 2019 and BIO One-on-One Partnering™@ JPM 2019 During the JP Morgan Healthcare Conference
  18. Can-Fite Enters Into Collaboration Agreement to Explore Namodenoson’s Anti-NASH Effect With Icahn School of Medicine at Mount Sinai in NYC
  19. Can-Fite Reports Third Quarter 2018 Financial Results and Provides Clinical Development Update
  20. Prior to Phase II Liver Cancer Data Release Can-Fite Brings on Board an Oncologist Expert